slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 6,211-6,240
Pages 296
Rows per page 30
Slide type
6,211-6,240 of 8,880
03
The slide uses a vertical bracket to group three key pillars under the umbrella of 'GENETICS'.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Loop · Logic Chain1 hit
12
The slide uses a process flow diagram to explain the 'POWER' methodology.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Logic Chain1 hit
14
The slide uses a process flow to demonstrate the predictive power of their genomic platform.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
15
FxG likely stands for Functional Genomics. The slide uses a process flow diagram to illustrate the R&D pipeline.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
24
The slide uses a three-column layout to present pharmacology, mechanism of action (diagram), and clinical development status.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
28
The chart demonstrates superior efficacy of 23ME-00610 over anti-PD1 in stimulating IFNy across multiple cancer types.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
29
The chart shows statistical significance (p<0.01 and p<0.0001) for the combination therapy.23andMe | Investor Presentation Deck | 39 slides · 23andMe
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
59
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
61
The slide uses a 3-pillar framework to explain the platform, then maps these to specific drug candidates with detailed mechanism-of-action descriptions.Immix Biopharma | Investor Presentation Deck | 62 slides · ImmixBio
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
05
TPD stands for Targeted Protein Degradation. The slide uses a three-column framework to explain their competitive advantage.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
08
The slide uses a biological pathway diagram to illustrate the mechanism of action for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
22
Includes a table of market data and a biological pathway diagram.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
34
Includes a waterfall plot showing p53WT cell dependency on MDM2 and a biological process diagram of the MDM2-p53 feedback loop.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
08
The slide uses a hub-and-spoke diagram to illustrate the ecosystem components surrounding the core vehicle offering.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
12
The slide outlines a two-track diagnostic process (FIT and Genetic) converging into a proprietary algorithm.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a biological process flow to explain the mechanism of action.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
10
Includes two heatmaps showing gene expression changes and a biological pathway diagram for GLP1 receptor activation.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
06
The slide uses a biological mechanism-of-action diagram to illustrate how the two components of PrimeC address specific cellular stressors in ALS.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Agitate1 hit
07
The slide uses a combination of a biological process diagram and a pharmacokinetic line chart to demonstrate drug synergy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
09
The chart highlights a 'Synchronized concentration peak' at 5 hours for both PrimeC components.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
22
The slide highlights the PARADIGM trial's research pillars, including proteomics, microRNA, exosomes, and neurofilaments, in partnership with institutions like MGH and Harvard.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
08
Includes a detailed biological pathway diagram created with BioRender.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
The slide uses a structural biology mechanism of action (MOA) comparison to demonstrate competitive advantage.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · CompetitionLoop · Quick Win Big Bet1 hit
18
Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
20
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 25 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
07
The slide uses a hub-and-spoke style diagram to show the flow of value between sellers, the platform, partners, and fans.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide uses a split-screen layout to contrast the 'Loyalty Program' and 'Gamified Engagement' pillars.Vivid Seats | Investor Presentation Deck | 24 slides · Vivid Seats
Pitch deck Investor relations Loop · Golden Circle1 hit